Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Britain Courts Anthropic Amid US Defense Department Dispute 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Apple Turns 50: From Garage Startup to AI Crossroads 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
CAMBRIDGE, Mass., June 28, 2017 -- Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, today announced the pricing of its initial public offering of 3,750,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. All of the shares are being offered by Aileron. In addition, Aileron has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of common stock from the company at the public offering price. Aileron’s common stock is expected to begin trading on the NASDAQ Global Market under the ticker symbol “ALRN” on Thursday, June 29, 2017.
BofA Merrill Lynch and Jefferies are acting as lead joint book-running managers and as representatives of the underwriters for the offering. William Blair and Canaccord Genuity are acting as co-managers for the offering. The offering is expected to close on July 5, 2017, subject to customary closing conditions.
A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission. This offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to this offering may be obtained by contacting: BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at [email protected] or Jefferies LLC, Attention: Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by emailing [email protected], or by calling 1-877-821-7388.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Aileron
Aileron is a clinical-stage biopharmaceutical company advancing stapled peptides, a novel class of therapeutics for cancers and other diseases. Our lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers. ALRN-6924, which is currently being tested in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDMX and MDM2.
Contact BMC Communications Brad Miles, 646-513-3125 [email protected]
